These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 10444280

  • 1. Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates.
    Scharrer I, Bray GL, Neutzling O.
    Haemophilia; 1999 May; 5(3):145-54. PubMed ID: 10444280
    [Abstract] [Full Text] [Related]

  • 2. Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A.
    Mauser-Bunschoten EP, van der Bom JG, Bongers M, Twijnstra M, Roosendaal G, Fischer K, van den Berg HM.
    Haemophilia; 2001 Jul; 7(4):364-8. PubMed ID: 11442640
    [Abstract] [Full Text] [Related]

  • 3. Frequent but low titre factor VIII inhibitors in haemophilia A patients treated with high purity concentrates.
    Zanon E, Zerbinati P, Girolami B, Bertomoro A, Girolami A.
    Blood Coagul Fibrinolysis; 1999 Apr; 10(3):117-20. PubMed ID: 10357004
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Plasma-derived versus recombinant factor concentrates in PUPs: a never ending debate?
    Berntorp E.
    Hamostaseologie; 2017 Jan 31; 37(1):53-57. PubMed ID: 27878207
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Meta-analysis on incidence of inhibitors in patients with haemophilia A treated with recombinant factor VIII products.
    Rota M, Cortesi PA, Steinitz-Trost KN, Reininger AJ, Gringeri A, Mantovani LG.
    Blood Coagul Fibrinolysis; 2017 Dec 31; 28(8):627-637. PubMed ID: 28678027
    [Abstract] [Full Text] [Related]

  • 8. Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.
    Hassan S, Cannavò A, Gouw SC, Rosendaal FR, van der Bom JG.
    J Thromb Haemost; 2018 Jun 31; 16(6):1055-1068. PubMed ID: 29665204
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan.
    Shirahata A, Fukutake K, Higasa S, Mimaya J, Oka T, Shima M, Takamatsu J, Taki M, Taneichi M, Yoshioka A, STUDY GROUP ON FACTORS INVOLVED IN FORMATION OF INHIBITORS TO FACTOR VIII AND IX PREPARATIONS.
    Haemophilia; 2011 Sep 31; 17(5):771-6. PubMed ID: 21682824
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Previously untreated patients and recombinant factor VIII concentrate studies.
    Pasi KJ.
    Blood Coagul Fibrinolysis; 1997 Aug 31; 8 Suppl 1():S29-32. PubMed ID: 9351534
    [Abstract] [Full Text] [Related]

  • 13. Timing and severity of inhibitor development in recombinant versus plasma-derived factor VIII concentrates: a SIPPET analysis.
    Peyvandi F, Cannavò A, Garagiola I, Palla R, Mannucci PM, Rosendaal FR, sippet study group.
    J Thromb Haemost; 2018 Jan 31; 16(1):39-43. PubMed ID: 29080391
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.
    Calvez T, Chambost H, d'Oiron R, Dalibard V, Demiguel V, Doncarli A, Gruel Y, Huguenin Y, Lutz P, Rothschild C, Vinciguerra C, Goudemand J, for FranceCoag Collaborators.
    Haematologica; 2018 Jan 31; 103(1):179-189. PubMed ID: 29025913
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison.
    Hay CRM, Palmer BP, Chalmers EA, Hart DP, Liesner R, Rangarajan S, Talks K, Williams M, Collins PW.
    Haemophilia; 2015 Mar 31; 21(2):219-226. PubMed ID: 25382829
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.